Vico begins twice-annual VO659 dosing in Phase 1/2 trial
The regimen is assessed over 12 months for safety, tolerability, pharmacokinetics and pharmacodynamics, and the FDA has cleared an IND for US trials.
See the latest news and media coverage for Vico Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Neurology genetic medicine company developing RNA-based therapies
vicotx.comLast updated
In short: Vico Therapeutics started twice-yearly VO659 dosing in a Phase I/IIa trial cohort.
The regimen is assessed over 12 months for safety, tolerability, pharmacokinetics and pharmacodynamics, and the FDA has cleared an IND for US trials.
VO659 reduces cerebrospinal fluid mutant huntingtin by 28% at day 85 in Huntington’s disease patients, with no sustained neurofilament light chain increase and generally good tolerability.
Led by Ackermans & van Haaren, funds advance VO659's Phase 1/2a trial in SCA3, SCA1 and Huntington's disease and pipeline expansion. Jeroen Vangindertael joins the board.
The trial evaluates VO659 in Huntington's disease and spinocerebellar ataxia types 1 and 3, expecting to enroll about 71 participants.
Vico Therapeutics begins twice-annual dosing of VO659 in HD, SCA3 & SCA1 patients. FDA IND cleared. First ASO targeting CAG repeat expansion across polyglutamine diseases.
LEIDEN, Netherlands, Sept. 13, 2024 /PRNewswire/ -- Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced new positive...
First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in 40 mg dose cohort with...
DUBLIN & PARIS--(BUSINESS WIRE)--Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key...
Track Vico Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Vico Therapeutics and other trending companies.